Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15508400 | 0.84 | NPSR1 (0.49) | TLR8TLR7KDM4EALDH1A1HPGD | |
| SCHEMBL15429565 | 0.81 | ALDH1A1 (0.38) | TLR8TLR7KDM4EALDH1A1LMNA | |
| SCHEMBL10735986 | 0.78 | KDM4E (0.37) | TLR8TLR7KDM4EALDH1A1HPGD | |
| SCHEMBL17229375 | 0.76 | KDM4E (0.42) | TLR8TLR7KDM4EALDH1A1LMNA | |
| SCHEMBL9287308 | 0.76 | TLR8 (0.55) | TLR8TLR7KDM4EALDH1A1LMNA | |
| SCHEMBL1684911 | 0.75 | TLR8 (0.44) | TLR8TLR7KDM4EALDH1A1LMNA | |
| SCHEMBL31042173 | 0.74 | ALDH1A1 (0.35) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL17221762 | 0.74 | TLR8 (0.43) | TLR8TLR7KDM4EALDH1A1LMNA | |
| SCHEMBL10379029 | 0.72 | DHFR (0.37) | — | |
| SCHEMBL2815642 | 0.72 | KDM4E (0.37) | KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018347-A1 | BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018347-A1 | BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE | MTOR, RICTOR, RPTOR | TLR8 4503/4885TLR7 3901/4885KDM4E 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.